Sumant Ramachandra - Oct 31, 2024 Form 4 Insider Report for Lyell Immunopharma, Inc. (LYEL)

Role
Director
Signature
/s/ Matthew Lang, as Attorney-in-Fact
Stock symbol
LYEL
Transactions as of
Oct 31, 2024
Transactions value $
$0
Form type
4
Date filed
11/1/2024, 04:56 PM

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LYEL Option (right to buy) Award $0 +260K $0.00 260K Oct 31, 2024 Common Stock 260K $0.96 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 One thirty-sixth (1/36th) of the shares of common stock subject to the option shall vest on a monthly basis following the date of grant on the same day of the month as such grant date (or on the last day of the month, if there is no corresponding day in such month), subject to the reporting person providing service through the applicable vesting date.